Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

Researchers randomly assigned patients to receive oral semaglutide gradually titrated to the maximal, 14-mg dose or placebo ... “Delivery of this tablet is more complicated than usual ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

You can use Wegovy (semaglutide ... Wegovy is 0.25 milligrams (mg). You’ll need to take 0.25 mg once per week for the first 4 weeks of treatment. Starting at this dosage reduces the risk ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide ... demonstrating a 14% reduction in risk of major ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly ...